Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma



Status:Recruiting
Conditions:Lymphoma, Lymphoma, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:12/14/2018
Start Date:November 30, 2017
End Date:April 2020
Contact:TG Therapeutics Clinical Support Team
Email:clinicalsupport@tgtxinc.com
Phone:212-554-4279

Use our guide to learn which trials are right for you!

A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma

This research study will evaluate the safety and efficacy of a study drug called Umbralisib
(also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia
and Marginal Zone Lymphoma that has come back or that has not responded to standard
treatment.


Inclusion Criteria:

- Confirmed diagnosis of Marginal Zone Lymphoma or Waldenstroms Macroglobulinemia

- Relapsed or refractory after at least one prior treatment regimen

- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2

Exclusion Criteria:

- Any major surgery, chemotherapy or immunotherapy within the last 21 days

- Evidence of hepatitis B virus, hepatitis C virus or known HIV infection

- Prior autologous stem cell transplant within 6 months of study entry
We found this trial at
4
sites
?
mi
from
New York, NY
Click here to add this to my saved trials
Boston, Massachusetts 02111
?
mi
from
Boston, MA
Click here to add this to my saved trials
Hackensack, New Jersey 07601
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Washington, District of Columbia 20007
?
mi
from
Washington,
Click here to add this to my saved trials